Exagen Inc. Prices Public Offering of Common Stock

Core Viewpoint - Exagen Inc. has announced a public offering of 3,350,000 shares of its common stock at a price of $5.25 per share, aiming to raise approximately $17.59 million before expenses [1]. Group 1: Offering Details - The offering consists of 3,350,000 shares, with gross proceeds expected to be $17,587,500 before deducting underwriting discounts and commissions [1]. - Exagen has granted underwriters a 30-day option to purchase an additional 502,500 shares under the same terms [1]. - The offering is expected to close on May 9, 2025, pending customary closing conditions [1]. Group 2: Underwriting and Registration - Canaccord Genuity is acting as the sole bookrunner for the offering [2]. - The public offering is made under a shelf registration statement on Form S-3, which was filed with the SEC on November 17, 2023, and declared effective on November 29, 2023 [3]. Group 3: Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on improving care for patients with chronic autoimmune conditions [5]. - The company's flagship product, AVISE® CTD, aids in the diagnosis of complex autoimmune diseases such as lupus and rheumatoid arthritis [5]. - Exagen emphasizes research, innovation, and patient-centered care in addressing autoimmune disease management challenges [5].